Skip to content

EBITDA at other companies

ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$46.67M+30.9%
Pfizer logo
PfizerPFE
Merck & Co. logo
Merck & Co.MRK
AbbVie logo
AbbVieABBV
Insmed logo
InsmedINSM
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio21.1×+18.7×

Where this comes from

Calculated from Innoviva, Inc.’s reported figures.

$38.2Mebit+
$6.6MDepreciation Depletion & Amortization
=$44.71M

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s EBITDA?
Innoviva, Inc. (INVA) reported EBITDA of $44.71M in Q1 2026.
How has Innoviva, Inc.'s EBITDA changed year-over-year?
Innoviva, Inc.'s EBITDA decreased by 6.7% year-over-year, from $47.9M to $44.71M.
What is the long-term trend for Innoviva, Inc.'s EBITDA?
Over 3 years (2021 to 2025), Innoviva, Inc.'s EBITDA has grown at a -21.2% compound annual growth rate (CAGR), from $388.94M to $189.96M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.